The effect of zaltrap in the treatment of retinal retinal vascular disorders resistant to Avasti
Phase 1
- Conditions
- H30-H36Retinal vascular disorders.Disorders of choroid and retina
- Registration Number
- IRCT2015081723651N1
- Lead Sponsor
- Investigator
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
Inclusion criteria :Eyes with active neovascularage-related macular degeneration (AMD) or diabetic macular edema (DME), best-corrected visual acuity of 20/100 (6/30) or less, the ability to comprehend the risks and benefits of the study, and the ability to sign the consent form; Exclusion criteria : Signs of ocular infection and a history of myocardial infarction or cerebrovascular accident.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Best corrected visual acuities. Timepoint: In the beginning of the study, and 1 day and 1 week after Zal-trap injection. Method of measurement: By the same examiner, using Snellen charts.
- Secondary Outcome Measures
Name Time Method The height of retinal pigment epithelium detachment. Timepoint: In the beginning of the study and 1 day and 1 week after Zal-trap injection. Method of measurement: On the horizontal scan and vertical scan passing through the foveola through averaging the horizontal and vertical measures.